Rituximab
Biologics may be useful for ocular inflammation
SAN FRANCISCO — Only adalimumab is FDA-approved for the treatment of noninfectious intermediate and posterior uveitis and panuveitis; however, other biologics hold promise for the treatment of ocular inflammation, according to a presentation at Cornea Subspecialty Day at the American Academy of Ophthalmology annual meeting.
GCA, Takayasu’s and polyarteritis nodosa: Implementing ACR guidelines
ATLANTA — A panel at ACR/ARP 2019 offered an overview of the new guidelines for giant cell arteritis, Takayasu’s syndrome, and polyarteritis nodosa.
Repeat rituximab superior to azathioprine for preventing relapse in ANCA-associated vasculitis
ATLANTA — Treatment with repeat doses of rituximab is superior to daily azathioprine for preventing relapse among patients with ANCA-associated vasculitis with a history of relapse, according to data presented at the 2019 ACR/ARP Annual Meeting.
Patients with pemphigus vulgaris more likely to achieve sustained complete remission with Rituxan
Managing adverse events from checkpoint inhibitors in a ‘data-free zone’
SAN DIEGO — Increasing use of checkpoint inhibitors in cancer therapy is leading to an uptick in immune-related adverse events for rheumatologists to manage, according to a presentation at the Congress of Clinical Rheumatology West.
Nintedanib approval provides 'exciting news' for other CTD-associated ILD
SAN DIEGO — A recent FDA approval for systemic sclerosis-associated interstitial lung diseases may portend a new hope for clinicians managing these complicated disorders, according to a presentation at the 2019 Congress of Clinical Rheumatology West.
Minimizing prednisone, nephrotoxic agents crucial for lupus nephritis outcomes
SAN DIEGO — Rheumatologists treating patients with lupus nephritis should make a concerted effort to reduce or avoid use of NSAIDs and other nephrotoxic drugs in order to improve long-term outcomes, according to a presentation at the 2019 Congress of Clinical Rheumatology West.
Infusion center patient experience growing more complex
GRAND RAPIDS, Mich. — As infusion centers have grown in complexity throughout the years, so too has the patient experience in these suites, with individuals often asked to take on a greater understanding of the clinical and financial impacts of their treatment, according to a presenter at the National Organization of Rheumatology Managers Annual Conference.
Infusion reactions to rituximab more significant in SLE than other diseases
Infusion reaction rates to rituximab may be more significant among patients with systemic lupus erythematosus than other diseases, according to findings published in BMC Rheumatology.